Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron (NASDAQ: REGN) announced a strategic collaboration with TriNetX to access TriNetX’s de-identified EHR network of approximately 300 million patients (about 170 million in the U.S.). Regeneron gains an exclusive opportunity to link RGC genomic and proteomic cohorts to this phenotypic dataset.
The deal enables expansion of Regeneron Genetics Center’s EHR-linked database, supports AI training for digital health solutions, and includes a Regeneron investment of up to $200 million. Data matching will follow applicable privacy laws including HIPAA and GDPR.
Regeneron (NASDAQ: REGN) announced FDA approval extending EYLEA HD (aflibercept) dosing intervals up to every 20 weeks (≈5 months) for wAMD and DME after one year of successful response, based on 96-week data from pivotal PULSAR and PHOTON trials.
Of patients completing week 96, 71% (wAMD) and 72% (DME) reached ≥16-week intervals; 47% (wAMD) and 44% (DME) reached ≥20-week intervals. Label now includes 96-week efficacy and safety; prefilled syringe review has an April 2026 target action date.
Regeneron (NASDAQ: REGN) will report first quarter 2026 financial and operating results on Wednesday, April 29, 2026 before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 AM ET that day.
According to the company, the webcast will be available on its Investors and Media page and telephone participation requires advance registration; a replay and transcript will be archived on the company website for at least 30 days.
Regeneron (NASDAQ: REGN) and Sanofi announced that Japan's MHLW approved Dupixent (dupilumab) for adults with moderate-to-severe bullous pemphigoid (BP), the first targeted therapy for BP in Japan and Dupixent's seventh Japanese indication.
Approval was based on the LIBERTY-BP-ADEPT Phase 2/3 trial where Dupixent plus corticosteroid taper showed sustained remission at Week 36 in 18% vs 4% with placebo (p=0.0250). Treatment-related adverse events occurred in 26% of Dupixent patients versus 15% for placebo; conjunctivitis was reported in 4% of Dupixent patients.
Regeneron (NASDAQ: REGN) and Society for Science honored 40 finalists in the 2026 Regeneron Science Talent Search, awarding more than $1.8 million to finalists and a $250,000 top prize to Connor Hill. Regeneron pledged an additional $150 million to extend title sponsorship through 2036, bringing total support for Regeneron STEM programs to over $300 million from 2017 to 2036.
Forty finalists received awards for original research across computational math, neuroscience, and blood cancer models; the competition recognized a total of $3.1 million in awards and named Colin Jie Chu the Seaborg Award winner.
Regeneron (NASDAQ: REGN) reported positive Phase 3 topline results from Hansoh's 48-week trial of olatorepatide in Chinese adults with obesity or overweight. The randomized, double-blind trial (N=604) met co-primary endpoints with up to 19% mean weight loss at week 48 and up to 97% achieving ≥5% weight loss.
The program showed favorable gastrointestinal tolerability (nausea 10%, vomiting <5%). Regeneron plans to initiate a global registrational Phase 3 program later in 2026; detailed data will be presented at a medical meeting. Safety and efficacy remain unevaluated by regulators.
Regeneron (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The session is available from the company’s Investors & Media page, with a replay and transcript archived for at least 30 days.
Regeneron and Sanofi (NASDAQ: REGN) announced a positive CHMP opinion recommending EU approval of Dupixent (dupilumab) to treat chronic spontaneous urticaria (CSU) in children aged 2–11 with inadequate response to H1 antihistamines and naive to anti-IgE therapy.
The opinion is supported by LIBERTY-CUPID Phase 3 data; a final EU decision is expected in coming months and a U.S. FDA decision is expected by April 2026.
Regeneron (NASDAQ: REGN) renews title sponsorship of the Regeneron Science Talent Search (STS) through 2036, pledging an additional $150 million and bringing its 20-year STS investment to $250 million. Combined STS and ISEF support totals more than $300 million from 2017–2036.
The renewal continues funding for STEM outreach, cites a 49% increase in STS entries since 2017, and notes engagement of over 20,000 students and recognition of 3,000 Regeneron scholars.
Regeneron (NASDAQ: REGN) and Sanofi announced FDA approval of Dupixent (dupilumab) on Feb 24, 2026 for treating allergic fungal rhinosinusitis (AFRS) in adults and children aged 6+ with a history of sino-nasal surgery.
Approval was based on a Phase 3 trial showing marked reductions in sinus opacification, nasal symptoms, polyp size, and a 92% reduction in risk of systemic corticosteroid use or surgery over 52 weeks.